Table 6.

Prediction of patient outcomes by FST in patients with elevated biomarker levels

VariableUrine NGAL>150 ng/ml (n=44)Urine TIMP-2×IGFBP-7>0.3 (n=32)
Patients, n (%)AUC±SEMP ValuePatients, nAUC±SEMP Value
Progression to AKIN stage 319 (43.2)0.86±(0.06<0.00111 (34.4)0.90±0.06<0.001
Receipt of inpatient RRT7 (15.9)0.91±0.06<0.0014 (12.5)0.91±0.080.009
Inpatient death12 (27.3)0.72±(0.100.035 (15.6)0.53±0.190.85
Progression to AKIN stage 3 or inpatient death24 (54.5)0.89±0.06<0.00114 (43.8)0.81±0.100.003